

Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

FITC anti-human CD3

RRID:AB_571906

Type: Antibody

Proper Citation

BioLegend Cat# 317305, RRID:AB_571906

Antibody Information

URL: http://antibodyregistry.org/AB_571906

Proper Citation: BioLegend Cat# 317305, RRID:AB_571906

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_571906

Vendor: BioLegend

Catalog Number: 317305

Alternative Catalog Numbers: 317306

Record Creation Time: 20250820T064209+0000

Record Last Update: 20250821T004415+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD3.

No alerts have been found for FITC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Shim BH, et al. (2026) Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells. Cell reports, 45(6), 117510.

Yang Z, et al. (2026) Macrophage-mediated brain-bone marrow crosstalk promotes chronic stress-induced glioma growth. Cancer cell.

Nicholas CA, et al. (2025) Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes. Cell reports, 44(4), 115425.

Lin S, et al. (2025) Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. iScience, 28(5), 112497.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell reports. Medicine, 6(10), 102399.

Zhou Y, et al. (2025) Glucose-1-phosphate promotes compartmentalization of glycogen with the pentose phosphate pathway in CD8+ memory T cells. Molecular cell, 85(13), 2535.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. Cell reports. Medicine, 6(12), 102510.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF- β 1 and IL-2 confer immunoregulatory functions to NK cells. iScience, 27(12), 111416.

Tieu V, et al. (2024) A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell, 187(5), 1278.

Xie Y, et al. (2024) The modified RNA base acp3U is an attachment site for N-glycans in glycoRNA. *Cell*, 187(19), 5228.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8⁺ T cell. *Cell reports*, 42(11), 113424.

Fierle JK, et al. (2021) Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1. *Cell reports. Medicine*, 2(8), 100362.